文献速递淋巴瘤

弥漫大B细胞淋巴瘤患者因非无效原因未完成R-CHOP方案治疗的结果与决定因素

Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma.
PubMed 文献 · Am J Hematol · 2020-04-03

结果显示5%患者在接受1-3周期后提前停止、5%在4-5周期后停止、84%完成计划治疗;年龄>75岁、体能状态差、结外病变及Charlson合并症指数≥1与未完成治疗显著相关,未完成治疗与生存期缩短强相关,1-3周期组5年总生存率为26%。

要点

  • 年龄>75岁、体能状态差、结外病变及合并症指数≥1预测非无效原因未完成R-CHOP治疗。
  • 未完成治疗与生存期缩短强相关,1-3周期组5年总生存率仅26%。
  • 需针对特定基线特征患者优化治疗耐受性以提高完成率。

核心结论

  • 因非无效原因未完成计划R-CHOP治疗是重要临床问题,与较差生存相关。

主要发现

  • 147例(5%)在接受1-3周期R-CHOP后因非无效原因提前停止,168例(5%)在接受4-5周期后停止,2639例(84%)完成计划治疗。
  • 195例(6%)因无效或治疗结束前死亡而未完成治疗。
  • 多因素逻辑回归显示年龄>75岁、体能状态差、结外病变及Charlson合并症指数≥1与未完成治疗显著相关。
  • 接受1-3周期患者的5年总生存率为26%(95%CI:19%-33%),4-5周期为49%(95%CI:41%-57%),完成治疗者为76%(95%CI:74%-77%)。

临床怎么用

  • 识别高龄、体能状态差、结外病变及合并症患者,优化治疗耐受性以提高完成率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with diffuse large B-cell lymphoma (DLBCL) who fail to complete planned treatment with R-CHOP due to toxicity are sparsely described. We investigated the extent of failure to complete treatment (six cycles or more, or three cycles + RT for patients with stage I disease) with R-CHOP for reasons unrelated to non-response, the determinants of such failure and the outcome among these patients. Three thousand one hundred and forty nine adult DLBCL patients who started primary treatment with R-CHOP were identified through the Swedish lymphoma register 2007-2014. Of these, 147 (5%) stopped prematurely after 1-3 cycles of R-CHOP for reasons unrelated to non-response, 168 (5%) after 4-5 cycles and 2639 patients (84%) completed planned treatment. Additionally, 195 (6%) patients did not complete treatment due to non-response or death before treatment end. In a multivariable logistic regression model, age > 75 years, poor performance status, extranodal disease and Charlson Comorbidity Index ≥1 were significantly associated with failure to complete planned R-CHOP treatment for other reasons than non-response. Non-completion of treatment strongly correlated with survival. Five-year overall survival for patients who received 1-3 cycles was 26% (95% CI: 19%-33%), 49% (95% CI: 41%-57%) for 4-5 cycles and 76% (74%-77%) for patients who completed treatment. Failure to complete planned R-CHOP treatment is an important clinical issue associated with inferior survival. Old age and poor performance status most strongly predict such failure. These results indicate a need for improved treatment tailoring for patients with certain baseline demographics to improve tolerability and chance for treatment completion.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Wästerlid T, Harrysson S, Andersson TM, et al. Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma. Am J Hematol. 2020. PMID: 32180274. doi:10.1002/ajh.25789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。